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The CARE Plus study – a whole-system
intervention to improve quality of life of
primary care patients with multimorbidity
in areas of high socioeconomic deprivation:
exploratory cluster randomised controlled
trial and cost-utility analysis
Stewart W. Mercer1*, Bridie Fitzpatrick1, Bruce Guthrie2, Elisabeth Fenwick3, Eleanor Grieve3, Kenny Lawson3,
Nicki Boyer3, Alex McConnachie4, Suzanne M. Lloyd4, Rosaleen O’Brien5, Graham C. M. Watt1 and Sally Wyke6
Abstract
Background: Multimorbidity is common in deprived communities and reduces quality of life. Our aim was to
evaluate a whole-system primary care-based complex intervention, called CARE Plus, to improve quality of life in
multimorbid patients living in areas of very high deprivation.
Methods: We used a phase 2 exploratory cluster randomised controlled trial with eight general practices in
Glasgow in very deprived areas that involved multimorbid patients aged 30–65 years. The intervention comprised
structured longer consultations, relationship continuity, practitioner support, and self-management support. Control
practices continued treatment as usual. Primary outcomes were quality of life (EQ-5D-5L utility scores) and well-being
(W-BQ12; 3 domains). Cost-effectiveness from a health service perspective, engagement, and retention were assessed.
Recruitment and baseline measurements occurred prior to randomisation. Blinding post-randomisation was not
possible but outcome measurement and analysis were masked. Analyses were by intention to treat.
Results: Of 76 eligible practices contacted, 12 accepted, and eight were selected, randomised and participated for the
duration of the trial. Of 225 eligible patients, 152 (68 %) participated and 67/76 (88 %) in each arm completed the
12-month assessment. Two patients died in the control group. CARE Plus significantly improved one domain of
well-being (negative well-being), with an effect size of 0.33 (95 % confidence interval [CI] 0.11–0.55) at 12 months
(p = 0.0036). Positive well-being, energy, and general well-being (the combined score of the three components)
were not significantly influenced by the intervention at 12 months. EQ-5D-5L area under the curve over the
12 months was higher in the CARE Plus group (p = 0.002). The incremental cost in the CARE Plus group was £929
(95 % CI: £86–£1788) per participant with a gain in quality-adjusted life years of 0.076 (95 % CI: 0.028–0.124) over
the 12 months of the trial, resulting in a cost-effectiveness ratio of £12,224 per quality-adjusted life year gained.
Modelling suggested that cost-effectiveness would continue.
(Continued on next page)
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Conclusions: It is feasible to conduct a high-quality cluster randomised control trial of a complex intervention
with multimorbid patients in primary care in areas of very high deprivation. Enhancing primary care through a
whole-system approach may be a cost-effective way to protect quality of life for multimorbid patients in
deprived areas.
Trial registration: Trial registration: ISRCTN 34092919, assigned 14/1/2013.
Keywords: Multimorbidity, Primary care, Deprivation, Socioeconomic, General practice, Longer consultations,
Care plan, Mindfulness, Empathy, Complex intervention
Background
Multimorbidity is more common, occurs earlier, and has
a higher burden in patients living in high deprivation
areas [1–3]. Primary care has a key role in managing
multimorbidity, but the continuing existence of the ‘in-
verse care law’ thwarts its impact in deprived areas, thus
contributing to pervasive and widening health inequal-
ities [4–7]. Consultations are more complex in deprived
areas but tend to be shorter [8–10], general practitioners
(GPs) feel more stressed, and patients with complex
needs are less enabled compared to those in more affluent
areas [9]. Due to the mismatch between patient need and
primary care capacity, GPs working in deprived areas suf-
fer more burn-out [11].
The evidence base for enhancing the care of patients
with multimorbidity is limited. A recent systematic re-
view found only 18 randomised controlled trials (RCTs)
worldwide on the management of multimorbidity in the
primary care setting [12]. There is a particular dearth of
evidence on multimorbidity in the context of deprivation.
We have previously shown that longer consultations for de-
prived patients with complex needs improved enablement
and reduced GP stress in a single practice in Scotland [13].
Patient-centred empathic approaches can also enhance
outcomes [14, 15]. Mechanisms of action may be direct
or indirect, operating, for example, through enablement
and self-management support [16, 17].
Improving well-being and quality of life in patients
with multimorbidity in deprived areas is likely to require
multiple inputs at system, practitioner and patient level
[18]. Such ‘whole-system’ approaches are likely to be even
more relevant in the context of deprivation and the inverse
care law. In a 4-year programme of research funded by the
Scottish Government, we have developed and optimised a
primary care-based whole-system intervention (CARE Plus)
to improve well-being and quality of life in multimorbid pa-
tients living in high deprivation areas, based on the Medical
Research Councils’ (MRC) complex intervention develop-
ment framework [19] and employing quantitative [2] and
qualitative [20, 21] methods to identify needs and to de-
velop and optimise the intervention in pilot work [22].
The aim of the current study was to carry out a phase
2 exploratory cluster RCT in general practice to test the
feasibility and likely cost-effectiveness of the intervention
in preparation for a large-scale definitive RCT. The key
research questions were:
(a) Is the sampling and recruitment of practices,
practitioners and patients feasible?
(b)Is it feasible to retain patients in the trial and follow
them up at 6 and 12 months in sufficient numbers
(response rate of 70 % or better)?
(c)What is the likely benefit and cost-effectiveness of
the complex intervention when trialled in a large,
definitive, cluster randomised trial?
Methods
Study design and participants
We performed a phase 2 cluster RCT to evaluate the
likely effectiveness and cost-effectiveness of the CARE
Plus intervention on patient outcomes and to assess en-
gagement and retention of practices and patients. Par-
ticipating general practices formed the cluster. Our aim
was to recruit eight practices. Practices were eligible if
they were in Glasgow and in the 100 practices in Scotland
(which has approximately 1000 practices in total) serving
the most deprived patients, based on the percentage of
registered patients in the 15 % most deprived postcodes.
Practices were excluded if they were unwilling to deliver
the intervention or could not attend the first training
session. The 76 eligible practices were sent details of
the study; 26 replied within 2 weeks, 12 were willing to
participate, and eight were selected based on previous
participation in quality-improvement initiatives.
Patients were eligible if they were aged between 30
and 65 years and had two or more long-term conditions.
The type of condition was not specified. Before random-
isation, participating practices were asked to identify ap-
proximately 25 patients per practice who met the above
inclusion criteria and who they believed would benefit
from and participate in the intervention. Exclusion cri-
teria were (a) unable to give informed consent including
those with severe learning disability, severe active mental
health problems (active psychosis, schizophrenia, bipolar
illness, psychotic depression, severe depression including
active suicidal ideation), severe dementia, or other severe
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cognitive impairments; (b) terminally ill or considered
by their GP as likely to die within next 12 months; and
(c) unable to understand spoken and written English.
Patients were recruited and baseline data collected
face-to-face before randomisation after written informed
consent was obtained. Patients could choose whether to
complete the follow-up questionnaires by post, telephone
or face-to-face. At follow-up, patients who did not return
mailed questionnaires within 10 days were telephoned to
establish their continuing participation and ascertain again
their preferred method for completing the questionnaire.
On completing each questionnaire, patients were given a
£5 gift voucher as a token of appreciation. Details of the
measures used are shown in Additional file 1. Implemen-
tation of CARE Plus consultations (intervention fidelity)
was estimated from the details recorded on the CARE Plus
care plan (see below), and the patient-reported question-
naire data (post-consultation and follow-up).
Randomisation and masking
The unit of randomisation was practice; the randomisation
schedule was generated by an independent statistician
within the Robertson Centre for Biostatistics after patients
gave consent and baseline data were collected. Practices
were ordered according to list size and randomised to
intervention or control within consecutive pairs, to avoid
an imbalance in list size between randomised groups. Due
to the intervention design it was not possible to mask
intervention allocation from the practitioners or the pa-
tients once the trial had started. The research nurses who
collected outcome data were blind to the treatment alloca-
tion at all stages, as were the trial analysts.
Development and optimisation of the CARE Plus
intervention
The intervention was developed according to MRC com-
plex intervention guidelines [19]. This included qualitative
interviews with GPs and practice nurses working in, and
multimorbid patients living in, deprived areas of Glasgow
[20,210] to understand how primary care might better re-
spond. From these, and the available evidence, we drew up
an outline of a whole-system intervention which included
longer consultations, a structured patient-centred em-
pathic approach, relational continuity, practitioner training
and support, and patient self-management support. We
then gathered views on the proposed intervention from
multimorbid patients, GPs and practice nurses in deprived
areas and from patient advocacy groups [22]. The inter-
vention was then piloted in two eligible practices not in
the main trial and further optimised [22].
The final CARE Plus intervention involved:
1. Changes to practice systems to allow longer
consultations (30–45 minutes) and relational
continuity with eligible multimorbid patients. Each
practice decided what changes would be necessary
to allow this; provided that they achieved the
intended aims, practices were allowed to decide on
how to implement this in their particular
organisational context.
2. Group-based practitioner support and training to
use the longer CARE Plus structured consultations
to carry out a holistic assessment, including
identification of patient concerns and priorities, a
focus on self-management, and agreeing on a care plan
(the CARE Approach [23]).
3. Additional patient self-management support materials
(mindfulness-based stress management CDs, a
cognitive behavioural therapy-derived self-help
booklet) and written material (also supplied on a
CD) about the intervention and the self-help material
(available on request from the corresponding author).
Practitioners were encouraged to link patients with
relevant local resources and community services when
appropriate. Follow-up consultations were arranged as
required with the same practitioner. Practitioners were
asked to give participating patients the self-management
support pack. Practitioners documented the details of
the consultations in the care plan, including consultation
length, problems explored and patient-identified goals.
Practitioner training and support for those in the
CARE Plus group involved three half-day meetings; one
at the start of the intervention and the other two spaced
out over the remaining 12 months. The intervention was
explained and discussed at the first meeting. Participants
set shared goals, and made personal learning plans based
on gaps in knowledge and/or skills. At the second and
third meetings, the group set shared goals for the session
and reviewed progress in the intervention. Case-based
discussions were encouraged to facilitate shared learning.
Two experienced practitioners facilitated the meetings,
one an academic GP (SWM) and the other a psychiatrist
with extensive expertise in managing patients with com-
plex needs. The sessions included 20–30 minutes of
mindfulness-based stress reduction for practitioners [24].
Outcomes
The primary patient-reported outcome measures were
health-related quality of life (EQ-5D-5L) [25] and well-
being (W-BQ12) [26]. The EQ-5D-5L was calculated as
a single preference-weighted utility score. The W-BQ12
has three components measured in its 12 items: negative
well-being, positive well-being, and energy. These
component scores can be combined to give an overall
general well-being score. Secondary patient-reported
outcomes were anxiety and depression (Hospital Anxiety
and Depression Scale, HADS [27]), self-efficacy [28] and
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self-esteem [29]. The baseline patient questionnaire in-
cluded demographic characteristics. Deprivation was esti-
mated by the Scottish Index of Multiple Deprivation
(SIMD) [30]. The level (number of conditions) and burden
(effect on daily life) of multimorbidity was assessed at
baseline [31] and expressed as the average mean score.
The level of engagement and retention of practices and
patients in the trial was also measured in terms of recruit-
ment and retention rates. Qualitative interviews with prac-
titioners and patients were also conducted but will be
reported in a separate paper.
Health service utilisation and prescribing data were ex-
tracted from the electronic medical records of participat-
ing patients for the 12 months before and 12 months
after the study began. This included all consultations
within the practice (with any healthcare professional,
whether face-to-face or by phone), and all out-patient
consultations and in-patient admissions.
Practitioners’ views on the training and support sessions
were collected 6 weeks after the last session using a scale
from 0 (not beneficial) to 4 (extremely beneficial) in terms
of overall benefit of training in meeting collective goals,
meeting personal goals, helping with participation in trial,
peer support, and helping deal with challenges.
Statistical and economic analysis
Patient characteristics at baseline were summarised by
intervention group as mean (standard deviation [SD]) or
frequency (per cent) for continuous and categorical out-
comes, respectively. Differences between the groups at
baseline were examined using regression models that ad-
justed for clustering at the practice level (linear models
for continuous variables and logistic models of dichot-
omous variables); variables with significant differences at
baseline (at the 10 % significance level) were adjusted for
in the analysis of outcome measures. Change from base-
line in the outcome measures was calculated as value at
follow-up (6 months or 12 months) minus baseline value.
Differences between the intervention and control groups
in the change from baseline values was tested separately at
each follow-up point using linear regression methods that
adjusted for the clustering of patients within practices as a
random effect. In addition, these models adjusted for base-
line value, age, sex and those baseline characteristics found
to be significantly different between the groups. From
these models, the mean difference (95 % confidence inter-
val [CI]) and p value are presented; effect sizes (95 % CI)
have also been derived for each outcome measure by
dividing the mean difference by the SD of the baseline
measure for all participants.
In addition, for the EQ-5D data, the area under the
curve (AUC) was derived at 6 and 12 months using the
available data. The AUC was analysed in a linear model
as described above. A within-trial cost-utility analysis
was carried out based on the EQ-5D-5L utility scores,
and on health service utilisation in control and interven-
tion groups. The evaluation was undertaken from the
NHS and Personal Social Service perspective favoured
by the National Institute for Health and Care Excellence
(NICE) [32]. The analysis estimated the cost-effectiveness
of the CARE Plus intervention compared with usual care
over the period of the trial (12 months). Differences in the
average utility change between the intervention and com-
parison groups gave an estimate of the quality-adjusted life
years (QALYs) gained from the intervention. The longer-
term cost-effectiveness of CARE Plus, using a discount
rate of 3.5 % [32], was estimated by extrapolating the
within-trial results over 2 years, and included a probabilis-
tic sensitivity analysis and value of information analysis to
account for uncertainty. Full details of the analysis and
further references can be found in Additional file 2.
Sample size calculation
As the current study was a planned phase 2 exploratory
trial intended to evaluate feasibility and to estimate the
required power for a phase 3 trial, we did not base the
sample size on a power calculation, given the paucity of
evidence on which to do this.
Data access
The trial statisticians (AM and SL) had full access to the
data. EF, EG, KL and NB had access to the economic
data. All other authors contributed to data interpretation.
Trial registration and ethical approval
The trial was registered with Current Controlled Trials
(ISRCTN 34092919). Due to an administrative error, the
registration was not applied for until the 28 November
2012 (6 weeks after the trial started) and was attained on
the 14 January 2013. Ethical approval was granted by the
West of Scotland Research Ethics Service, reference
number 11/WS/0031, prior to the start of the trial.
Results
Baseline characteristics of practices and patients
The practices in the intervention and control groups
were of similar size in terms of the mean number of reg-
istered patients, with 3605 (SD 1338.1) patients in the
intervention versus 3710 (SD 1748.9) in the control. Par-
ticipating practices ranged from the fifth to the 62nd
most deprived practices in Scotland. Mean deprivation
(SIMD) scores for all registered patients were 52.35 (SD
5.70) in the intervention practices, compared to 49.23
(SD 8.93) in the control practices. Deprivation scores for
patients in the trial were not significantly different from
the practice means (Table 1). Participating patients had a
mean age of 52 years with a mean of five long-term con-
ditions each. Patients’ characteristics and baseline
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measures did not differ significantly between the interven-
tion and control groups (see Table 1 and Additional file 1).
Primary patient-reported outcomes
As shown in Table 2, after adjusting for baseline variables
there was a significant difference in EQ-5D-5L utility score
at 6 months (p = 0.039) in favour of the CARE Plus group,
although this was no longer significant at 12 months
(p = 0.15). There was a significant difference in one of
the three components of the W-BQ12 (p = 0.004) in
favour of the CARE Plus group at 12 months, signifying a
reduction in negative well-being relative to controls.
Positive well-being, energy and general well-being (the
combined score of the three components) were not sig-
nificantly influenced by the intervention at 6 or
12 months, though the trend was in favour of the
CARE Plus group by 12 months (Fig. 1).
Cost-utility analysis based on EQ-5D-5L
When measured as AUC, there was a significant differ-
ence between the EQ-5D-5L scores over the 12-month
period, in favour of the CARE Plus group (p = 0.002; ef-
fect size 0.36) (Fig. 1). The within-trial cost-utility ana-
lysis estimated the immediate impacts (in terms of costs
and effects) associated with the CARE Plus intervention
compared with usual care. The total costs associated
with the CARE Plus group were estimated to be £312,449
compared to total costs for usual care of £243,793. The
CARE Plus group was associated with an increase in total
costs of £82,989 compared to a slight increase in costs for
Table 1 Participating patient characteristics
Characteristics Usual care (N = 76) CARE Plus (N = 76) p value for difference between groups
Sex:
Female 39 (51 %) 46 (61 %) 0.35
Male 37 (49 %) 30 (39 %)
Age:
Mean (SD) 53.1 (8.0) 51.9 (9.6) 0.52
<50 22 (29 %) 28 (37 %)
50–59 34 (45 %) 28 (37 %)
≥ 60 20 (26 %) 20 (26 %)
Index of Multiple Deprivation:
Mean (SD) 52.8 (21.9) 49.8 (22.0) 0.54
Q1 (least deprived) 2 (3 %) 2 (3 %)
Q2 1 (1 %) 3 (4 %)
Q3 4 (5 %) 5 (6 %)
Q4 7 (9 %) 8 (11 %)
Q5 (most deprived) 61 (82 %) 57 (76 %)
Number of chronic conditions:
Mean (SD) 5.1 (2.1) 4.8 (2.6) 0.51
2 7 (9 %) 14 (18 %)
3 12 (16 %) 11 (14 %)
4 14 (18 %) 18 (24 %)
5 13 (17 %) 12 (16 %)
≥6 30 (40 %) 21 (28 %)
Burden of multimorbidity
Mean (SD) 3.1 (1.0) 3.2 (1.1) 0.40
Primary patient outcomes
EQ5D-5 L 0.419 (0.325) 0.419 (0.318) 0.99
W-BQ12 General Well-being Score (total) 16.0 (8.0) 14.3 (9.0) 0.29
W-BQ12 Negative Well-being Score 5.1 (3.5) 6.3 (4.1) 0.14
W-BQ12 Energy Score 3.2 (2.7) 3.1 (2.8) 0.86
W-BQ12 Positive Well-being Score 5.8 (3.5) 5.7 (3.7) 0.79
Summary statistics are presented as mean (SD) or number (per cent)
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usual care of £487, giving an incremental cost of £82,501
and an adjusted mean difference of £929 (95 % CI £86–
£1788) per participant. CARE Plus was more effective in
terms of QALYs with a gain of 0.076 QALYs (95 % CI
0.028–0.124) over the 12 months of the trial. As a result,
the CARE Plus intervention was associated with an in-
cremental cost-effectiveness of £12,224 per QALY
gained. The cost-effectiveness acceptability curve (Fig. 2)
illustrates the probability that the CARE Plus intervention
was cost-effective for any given value of the cost-effect-
iveness threshold. For a cost-effectiveness threshold of
£20,000/QALY, the probability that CARE Plus was cost-
effective (compared to usual care) was 0.79, and this rose
to 0.93 for a cost-effectiveness threshold of £30,000/
Table 2 Primary outcomes at 6 and 12 months in control and intervention groups
Outcomes Change from baseline Adjusteda mean
difference (95 % CI)
Effect size (95 % CI) p value
Usual care CARE Plus
Primary outcomes:
6 months
EQ5D-5 L −0.08 (0.27) 0.04 (0.25) 0.13 (0.01, 0.25) 0.38 (0.00, 0.75) 0.039
W-BQ12 General Well-being −1.3 (5.1) −0.2 (6.5) 0.70 (−2.45, 3.85) 0.08 (−0.28, 0.44) 0.66
W-BQ12 Negative Well-being 1.0 (2.8) 0.0 (2.9) −0.69 (−1.63, 0.24) 0.18 (−0.06, 0.42) 0.14
W-BQ12 Energy 0.7 (2.8) 0.2 (2.7) −0.42 (−1.85, 1.01) −0.15 (−0.65, 0.36) 0.56
W-BQ12 Positive Well-being −0.9 (2.8) −0.5 (3.5) 0.66 (−0.31, 1.64) 0.18 (−0.09, 0.46) 0.18
12 months
EQ5D-5 L −0.02 (0.28) 0.02 (0.26) 0.06 (−0.02, 0.14) 0.14 (−0.10, 0.39) 0.15
W-BQ12 General Well-being −1.6 (5.6) 0.4 (6.8) 1.99 (−0.27, 4.24) 0.23 (−0.03, 0.49) 0.083
W-BQ12 Negative Well-being 1.2 (2.8) −0.2 (2.5) −1.30 (−2.16, −0.43) 0.33 (0.11, 0.55) 0.0036
W-BQ12 Energy 0.6 (2.4) 0.6 (2.9) 0.31 (−0.55, 1.17) 0.11 (−0.20, 0.42) 0.47
W-BQ12 Positive Well-being −0.8 (3.3) −0.6 (3.8) 0.57 (−0.56, 1.70) 0.16 (−0.16, 0.48) 0.32
aMean differences were adjusted for baseline score, age, gender and Hospital Anxiety and Depression Scale caseness - positive effects sizes indicate a difference
in favour of the intervention group.
CI confidence interval
Fig. 1 Primary outcomes: quality of life and well-being at 12 months
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QALY. Modelling of estimated effects 2 years beyond the
trial period suggested that this cost-effectiveness would be
likely to continue in the longer term (see Additional file 2).
Secondary patient outcomes
None of the secondary outcomes were significantly dif-
ferent between intervention and control groups, though
anxiety (p = 0.08) and depression (p = 0.06) measured by
the HADS were of borderline significance in favour of
the CARE Plus group, although the effects sizes were
relatively small. Self-esteem and self-efficacy showed the
least evidence of change. Full details of all outcomes are
shown in Additional file 1.
Engagement and retention
All eight practices remained in the study for the 12-
month study period. Outcome data were collected on
90 % of patients at 6 months (91 % in the intervention
group and 89 % in the control group) and 88 % (in both
groups) at 12 months (Fig. 3). Practices in the interven-
tion group engaged well with the training and support
meetings, with all nine GPs and practice nurses involved
in delivering the intervention attending training sessions
1 and 2, and 78 % (7/9) attending the final training ses-
sion. Seventy eight per cent (7/9) of participating staff
responded to the evaluation of the training, reporting
mean scores (out of 4) of 3.4 (SD 0.54) for overall benefit
of training, 3.6 (SD 0.54) for meeting collective goals, 3.3
(SD 0.95) for meeting personal goals, 3.4 (SD 0.79) for
helping with participation in the trial, 3.4 (SD 0.79) for
peer support, and 3.3 (SD 0.95) for helping deal with
challenges.
Implementation of CARE Plus consultations (interven-
tion fidelity) was estimated from the care plan and the
patient report data. Both sources of data confirmed that
the CARE Plus patients received substantially longer initial
consultations; with a mean length of 36.9 minutes (SD
9.8), according to the care plan, and a mean 34.1 minutes
(12.7) according to the patient report. The mean consult-
ation length for the second and third consultations were
29.4 (SD 13.0) and 22.3 (SD 8.4), respectively. The total
amount of time in the CARE Plus consultations per pa-
tient was on average 69.2 (SD 30.18, n = 54). The number
of CARE Plus consultations recorded per patient varied
from one to six; 22 % received one consultation, 40 % re-
ceived two, and 38 % receiving three or more. Patients saw
the same practitioner in all CARE Plus consultations. The
mean number of consultations over the 12-month period
was eight in the CARE Plus group (two CARE Plus and
six non-CARE Plus consultations) and eight in the usual
care group. Healthcare practitioners reported giving the
self-management pack to 97 % of patients over the course
of the CARE Plus intervention; 71 % of patients reported
having received this in the 12-month follow-up question-
naire. Practitioners reported signposting patients to local
community self-management resources in 49 % of CARE
Plus consultations; 45 % of patients reported receiving
this advice.
Two patients died in the usual care group during the
course of the study; one from the sequelae of a stroke after
several months in hospital, and one (who was under the
care of a cardiologist and a diabetologist) from an acute
myocardial infarction.
Discussion
A primary care-based complex intervention to improve
well-being and quality of life targeted at very deprived
patients with multimorbidity was tested in a phase 2 ex-
ploratory cluster RCT. The intervention consisted of sys-
tem changes to allow structured longer consultations and
relationship continuity, group-based training and support
for practitioners, and self-management support material
Fig. 2 Economic cost-effectiveness acceptability curve for CARE Plus intervention
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for patients. The findings provide preliminary evidence of
effectiveness and cost-effectiveness of the intervention and
demonstrate the feasibility of carrying out a high-quality
trial in a very challenging context. The main effect of the
intervention appeared to be to limit the decline in quality
of life and well-being seen in the control group.
A recent pilot study of a culturally sensitive well-being
intervention for underserved patients in primary care
showed some evidence of acceptability and efficacy but
had major problems with recruitment and engagement
[33]. A key component of our intervention was substan-
tially longer consultations, adding to the limited evidence
base on the possible benefits of more time for such pa-
tients [34, 35]. A large primary care-based RCT that aimed
to enhance self-management in general practice in a rela-
tively high deprivation setting with multimorbid patients
failed to show any benefit [36]. Unlike the CARE Plus
study, it did not include longer consultation time with the
GPs. Thus, increasing consultation length may be crucial
in delivering better care, including self-management
support, in this population. The effect sizes of the primary
outcomes that were significant in the current study (0.38
for EQ-5D-5L at 6 months, 0.33 for W-BQ12 at 12 months)
were slightly larger than recently reported for a collabora-
tive care approach for multimorbid patients in deprived
areas in England (adjusted effect size 0.30) [37]. A recent
small feasibility RCT (n = 50) in Ireland of an occupational
therapist-led self-management support intervention for
multimorbid patients also reported benefit [38]. However,
neither study reported cost-effectiveness. The CARE Plus
intervention was associated with an incremental cost-
effectiveness of £12,224 per QALY gained, well below
the threshold range of £20,000–£30,000 per QALY used
by NICE to recommend NHS implementation in England
and Wales [39]. Modelling suggested that this cost-
effectiveness would be likely to continue in the longer
term (see Additional file 2).
The importance of developing and optimising the inter-
vention along MRC guidelines using mixed methods and
working in partnership with all the key stakeholders should
be emphasised [19]. Our intervention was developed sys-
tematically in a programme of work that (a) used large-
scale epidemiological data to identify the target population
[2]; (b) used qualitative methods to gain the views and per-
spectives of practitioners and patients to identify the main
problems and potential solutions [20, 21]; and (c) consulted
a range of stakeholders on the likely acceptability of the ini-
tial intervention, and used these views and pilot studies to
further optimise the intervention [22]. Although this
process took a considerable amount of time (54 months
including the exploratory RCT), we believe this was very
important in terms of ‘co-designing’ and refining a bespoke
Fig. 3 Trial flow chart
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complex intervention that was acceptable to practitioners
and patients.
A major strength of this study is the high level of reten-
tion that we achieved in terms of practices and patients
who are conventionally regarded as difficult to engage in re-
search. The amount of work required to collect the patient
outcome data was substantial (see Additional file 1: Table
S4) Given the small number of studies conducted in pri-
mary care on multimorbid patients in general, and in areas
of high deprivation in particular, this study is important in
demonstrating that such research can be done to a high
level of quality in such settings if adequately resourced.
Given the context of an exploratory phase 2 trial intended
to examine feasibility and provide an initial estimate of ef-
fectiveness to power a definitive trial, inevitable weaknesses
include the relatively small number of practices and pa-
tients involved and relatively short trial period.
A possible weakness in the trial was the possibility of
un-blinding of the research nurses who did face-to-face
or telephone follow-up at 6 months and 12 months. This
was not measured, but almost two-thirds of follow-up
was done by postal questionnaire (see Additional file 1:
Table S4) in which un-blinding was not possible.
Our economic analysis took a standard approach and did
not attempt to measure any benefits of the intervention in
terms of family and community benefit resulting from the
improved quality of life and well-being in these vulnerable
patients. There may have also been benefits for practitioners
in being supported to deliver more effective care, which has
the potential to enhance practitioner well-being and reduce
practitioner stress and burn-out [9, 11], and perhaps even
enhance workforce retention in deprived areas.
Proceeding to a definitive phase 3 trial would appear
to be feasible and warranted, given the high burden of
multimorbidity in deprived areas on healthcare costs
[39] and the very limited evidence base on interventions
[12, 40, 41]. Our value of information analysis also
suggests this would be good value for money in terms
of research investment (see Additional file 2).
Conclusion
A complex whole-system intervention in primary care to
enhance well-being and quality of life in patients with
multimorbidity in deprived areas has been developed
and evaluated in a cluster randomised phase 2 trial,
demonstrating feasibility and plausible benefit. As far as
we are aware, this is the first study in the world of its
kind. It shows that high-quality RCTs of complex inter-
ventions can be done in patients who have the highest
needs due to complex problems and living in areas of
extreme deprivation. Enabling practices in deprived
areas to provide longer and more patient-centred care
for multimorbid patients may protect quality of life in a
cost-effective way.
Additional files
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